Clinical Nutrition
Strategic Growth Drivers
Portfolio Innovation
~$120M
2023 New Product Revenue¹
Accelerate launch
cadence and expand
products globally
Baxter
NUMETA
Market Development
Generate clinical evidence
to show broader benefits
of PN
Drive therapy adoption
through peer-to-peer
educational programs
iCAN
Enter Adjacencies +
Targeted products for
pre-term infants
Increase adoption of
nutrition in Oncology
Introduce subcutaneous
administration
Innovation, Increased Adoption And Expansion Of Parenteral Nutrition
Drive Above-Market Growth Of 4% - 5% Through 2023²
¹All references to "new products" in this presentation include new product launches, line extensions and geographic expansions, unless otherwise noted. 2All references in this presentation to future
financial expectations assume commercial execution and regulatory approvals, as applicable, consistent with Baxter's plans. CAGRS for years 2018-2023 assume constant foreign exchange rates.
| 6View entire presentation